Scarica l'app Stockscreener
27.07
0.24%
-0.075
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$27.14
Aprire:
$27.055
Volume 24 ore:
18.25M
Relative Volume:
0.38
Capitalizzazione di mercato:
$153.88B
Reddito:
$62.58B
Utile/perdita netta:
$7.79B
Rapporto P/E:
19.97
EPS:
1.3551
Flusso di cassa netto:
$10.38B
1 W Prestazione:
-1.08%
1M Prestazione:
+5.56%
6M Prestazione:
+7.70%
1 anno Prestazione:
+1.25%
Intervallo 1D:
$26.73
$27.29
Intervallo di 1 settimana:
$26.36
$27.42
Portata 52W:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.07 | 154.31B | 62.58B | 7.79B | 10.38B | 1.3551 |
|
LLY
Lilly Eli Co
|
1,031.74 | 983.12B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
245.01 | 593.51B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.12 | 403.74B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
206.22 | 320.30B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
167.50 | 318.87B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Advanced Drug Delivery Market to Grow 10.2% Annually Through 2030 - GlobeNewswire Inc.
Pfizer (PFE) Stock Holds Near $27.14 After Q4 2025 Beat, Reaffirms 2026 Guidance Amid COVID Decline - International Business Times Australia
Pfizer Terminates Early-Stage Ulcerative Colitis Drug Study: What Investors Should Watch - TipRanks
Pfizer (PFE) Receives "Underperform" Rating from RBC Capital | P - GuruFocus
Pfizer secures rights to new GLP-1 as obesity push gathers pace - The Pharma Letter
FDA Approves Pfizer’s Braftovi Combination for First-Line Metastatic Colorectal Cancer - Contract Pharma
FDA grants full approval to Pfizer’s colorectal cancer treatment | 2026-02-25 | Investing News - Stockhouse
Pfizer Stock: Is PFE Underperforming the Healthcare Sector? - Barchart.com
FDA grants full approval to Pfizer’s Braftovi combo - The Pharma Letter
Antipyretics Market Is Going to Boom | Pfizer Inc. • GlaxoSmithKline plc • Sanofi S.A - openPR.com
Is Pfizer (PFE) Offering Value After Mixed Multi Year Share Price Performance - Yahoo Finance
ARVINAS, INC. SEC 10-K Report - TradingView
RBC Capital initiates Pfizer stock with underperform on revenue concerns - Investing.com India
RBC Capital initiates Pfizer stock with underperform on revenue concerns By Investing.com - Investing.com UK
Pfizer Gets Full FDA Approval for Braftovi Combination for Colon Cancer Treatment - marketscreener.com
Pfizer wins full FDA approval for Braftovi in colon cancer By Investing.com - Investing.com South Africa
Pfizer Inc. Announces U.S. FDA Grants Full Approval to its BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer - marketscreener.com
Pfizer Secures $495 Million China Obesity Drug Deal - GuruFocus
U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer - Eagle-Tribune
FDA Grants Full Approval for Pfizer's Braftovi in Colorectal Can - GuruFocus
Pfizer wins full FDA approval for Braftovi (PFE:NYSE) - Seeking Alpha
This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income - The Globe and Mail
Helus Pharma appoints former Pfizer chief medical officer to board of directors - marketscreener.com
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee - Yahoo Finance
Pfizer Adds Sciwind As China Partner For New Weight Loss Drug - Forbes
Paresthesia Treatment Market Is Going to Boom |Pfizer Inc, Novartis AG, GSK plc, Merck & Co Inc - openPR.com
Effervescent Tablet Market Is Going to Boom |• Bayer AG • Pfizer Inc. - openPR.com
Pfizer Nabs China Obesity Drug Rights in $495 Million Deal - Bloomberg.com
Aiming at a Billion-Dollar Market, Pfizer Doubles Down on Obesity Therapies in China - NAI500
Sciwind Partners with Pfizer to Commercialize Ecnoglutide in China - Intellectia AI
Sciwind Biosciences Partners Pfizer China To Commercialize Ecnoglutide - Nasdaq
Pfizer secures China rights to obesity drug in US$495 mil deal - The Edge Malaysia
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China - Yahoo Finance
Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results - Yahoo Finance
Pfizer (PFE) Secures Licensing Deal with Sciwind for Diabetes Dr - GuruFocus
Pfizer in diabetes drug deal with Sciwind Biosciences - The Economic Times
Pfizer Leadership to Outline Strategy at Key Healthcare Forum - AD HOC NEWS
Pfizer, Inc. (PFE) Stock Analysis: A Glimpse into Potential 7.18% Upside with Robust Dividend Yield - DirectorsTalk Interviews
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - The Joplin Globe
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Pfizer stock slips in premarket as tariff jitters hit futures and weight-loss race resurfaces - Bez Kabli
Telescope Innovations Installs Second Self-Driving Lab at Pfizer - TMX Newsfile
Pfizer’s Comirnaty Update: What U.S. Patients Really Need to Know Now - AD HOC NEWS
Assessing Pfizer (PFE) Valuation As Investors Revisit Mixed Returns And Oncology Growth Prospects - simplywall.st
Massive News: Pfizer's 6% Dividend Could Be Safer Than You Think - Nasdaq
Stevens Capital Management LP Makes New Investment in Pfizer Inc. $PFE - MarketBeat
Pfizer Ltd: India Arm Pops on Strong Q3—But Is It a Buy for US Investors? - AD HOC NEWS
Pfizer: A Risky 6.3% Yield For Income-Oriented Investors - Seeking Alpha
Is Pfizer Stock an Underrated Healthcare Investment Play? - The Globe and Mail
Pfizer (PFE) Among Pharma Giants Securing Tariff Exemption - GuruFocus
Pfizer (PFE) Stock Falls to $26.59 as Barclays Sets $25 Target — Can Oncology Growth Offset Patent Loss Risks? - Swikblog
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.70%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):